It is totally absurd to run *after* the future, predicted or expected mutation to base your vaccines.
You can't make new vaccine just based on general knowledge that next VOC will likely contain an escape mutation to some unknown amino acid at the few possible sites. 1/
Experts like @jbloom_lab can predict (& they have predicted correctly in the past) what sites are likely to play key roles in future antigenic evolution, but to make a vaccine, you need to predict an exact future sequence. 2/
And we may *never* be able to predict the complete genetic makeup of a future variant. It's not just technical limitations that hamper evolutionary prediction. We don't really know how predictable #SARS2 evolution is even in principle. 3/
Then, why not adopt other approaches to develop next generation vaccines. Like selecting certain conserved epitopes to develop a pan-sarbecovirus vaccine. Or develop a multi-pronged vaccine. Or an infection blocking mucosal vaccine? 4/
These mosaic/cocktail vaccines are currently envisioned as a way to get a broader response, but you could also imagine that they might reduce burden to get any given prediction exactly correct (if there are a lot of components). 6/ @jbloom_lab
The major limitation of current vaccines is their inability to block infection and transmission of rapidly evolving SARS2 virus.
Just imagine…. 7/
…how different the last few years might have been had a vaccine capable of blocking the SARS2 virus been administered to workers at the Huanan Market in Wuhan—where, scientists suspect, a raccoon dog infected a vendor & set off a pandemic that has killed >6.3 million people 8/
And we know…long before COVID-19 transformed daily life, scientists were aware of the possibility that a coronavirus could make the leap from an animal species to the human population. 9/
If you do want to read ONE paper/study this weekend, please go through this 🧵on an amazing work done by @BoytonRosemary@Daltmann10 & colleagues that has shaken the entire academic world! See the link👇 1/
When the process of developing new COVID19 vaccines started in 2020, the two threats to their success that most vaccine experts feared were: Antibody Driven Enhancement (ADE) and Original antigenic sin aka Antigenic Imprinting 2/
Fortunately, the first immune phenomenon (#ADE) that had marred the reputation of one Dengue vaccine and few candidates ag RSV & others, is yet to be observed with current Covid vaccines. 3/
That’s true. They are not completely redundant. Serving their purpose for individual protection to certain extent. That’s fine for an endemic entity, but not ideal for pandemic situations
There are other issues also with the current vaccines…like the durability of protection…
Another interesting study on the #SARS2 persistence in the human body after acute infection is over 👇 1/
Researchers performed autopsies on 44 patients with COVID19 to map and quantify SARS2 distribution, replication, and cell-type specificity across the human body, including brain, from acute infection through over seven months following symptom onset. 2/
What did they find?
SARS2 is widely distributed, even among patients who died with asymptomatic to mild COVID-19, and that virus replication is present in multiple extrapulmonary tissues early in infection. 3/
This is one of the most debatable issues faced by the Covid vaccine developers, experts & agencies following the Omicron’s emergence. 1/
Whether to change the formulation or not depends on the memory B cells (Bmem) responses to Spike protein & how 'original antigenic sin' (OAS) complicates this 2/
The emergence of variants provides a challenge to the current vaccines and vaccination strategies because there is a risk of decline in vaccine efficacy as the number of mutations within Spike epitopes rises. 3/
People infected with SARS2 had more than 3 times the risk of dying over the following year compared with those who remained uninfected. 1/
Short-term mortality (up to 5 weeks post-infection) was significantly higher among COVID-19 group than in the reference group 2/
For COVID19 cases aged 60 years or older, increased mortality persisted until the end of the first year after infection, and was related to increased risk for CVS, cancer, respiratory system diseases & other causes of death. 3/